What non‑proton‑pump inhibitor treatment options are appropriate for a patient with dyspeptic symptoms who wants to avoid PPIs due to a remote history of Clostridioides difficile infection?

Non-PPI Treatment Options for Dyspepsia in Patients Avoiding PPIs

For a patient with dyspeptic symptoms who wants to avoid PPIs due to remote CDI history, start with H. pylori testing and eradication if positive, followed by H2 receptor antagonists (H2RAs) as first-line acid suppression, then consider tricyclic antidepressants (TCAs) if symptoms persist.

Addressing the CDI Concern

While your patient's concern about CDI recurrence is understandable, the most recent high-quality randomized controlled trial evidence shows PPIs do not significantly increase CDI risk (OR 1.29,95% CI 0.82-2.02; p=0.27) 1. However, observational data from critically ill populations suggests a possible association 2, 3, though this may reflect confounding by indication rather than causation. The 2022 AGA guideline notes that higher-dose PPIs have been "more strongly associated" with CDI, but emphasizes "there is no direct evidence of a causal relationship" 4.

Given the patient's strong preference and remote history, respecting their wishes while providing effective alternatives is the appropriate clinical approach.

Algorithmic Treatment Approach

Step 1: Test and Treat H. pylori

• Perform stool antigen or urea breath test
• If positive, eradicate with appropriate antibiotic regimen
• This addresses a definitive treatable cause and may resolve symptoms entirely 5, 6

Step 2: H2 Receptor Antagonists (First-Line Acid Suppression Alternative)

• Use H2RAs instead of PPIs for acid suppression
• Recent 2025 data shows H2RAs carry significantly lower CDI risk than PPIs (RR: 1.86 for PPIs vs H2RAs) 3
• Trial for 4-8 weeks 6, 7
• H2RAs are less potent than PPIs but avoid the patient's concern while providing acid suppression
• Common pitfall: H2RAs develop tachyphylaxis with continuous use; consider intermittent dosing if long-term therapy needed

Step 3: Tricyclic Antidepressants (Neuromodulators)

• If H2RAs fail, TCAs are the next evidence-based option
• The 2022 BSG guideline suggests "head-to-head trials of TCAs vs acid suppressant drugs" as first-line therapy 5
• TCAs work through neuromodulation rather than acid suppression, addressing visceral hypersensitivity
• Start low-dose (e.g., amitriptyline 10-25 mg at bedtime), titrate gradually
• Continue for 6-12 months if effective 6
• This is particularly appropriate for functional dyspepsia, which is the likely diagnosis if endoscopy is negative

Step 4: Prokinetic Agents (If Available)

• Consider if postprandial distress syndrome predominates (early satiety, postprandial fullness)
• Options include metoclopramide (short-term only due to tardive dyskinesia risk) or domperidone (where available)
• Newer agents like acotiamide show promise but availability varies 8
• Caution: Limited availability and side effect profiles restrict routine use 6

Step 5: Psychological Therapies

• Cognitive behavioral therapy (CBT) or gut-directed hypnotherapy
• Increasingly recognized as effective for functional dyspepsia 9
• Can be used alone or combined with medications
• Particularly valuable for refractory symptoms

Additional Considerations

Dietary and Lifestyle Modifications

• Avoid overly restrictive diets (risk of malnutrition) 5
• Identify and eliminate specific trigger foods through systematic trial
• Regular exercise may provide benefit 5

When to Reconsider Endoscopy

• Age >55 years at symptom onset
• Alarm features: weight loss, dysphagia, vomiting, anemia, family history of upper GI malignancy 5, 7
• Failure to respond to empiric therapy

Emerging Therapies

• Fundic accommodation agents (buspirone) 8
• Ghrelin agonists and 5-HT4 agonists under investigation 5
• These may become options if standard therapies fail

Key Clinical Pitfalls to Avoid

1. Don't dismiss the patient's CDI concern even though RCT evidence is reassuring—patient autonomy and shared decision-making are paramount
2. Don't use prokinetics long-term without careful risk-benefit assessment due to serious adverse effects
3. Don't forget H. pylori testing—this is a potentially curative intervention
4. Don't continue ineffective therapy indefinitely—reassess after 4-8 weeks and move to next step
5. TCAs are underutilized in functional dyspepsia despite good evidence; consider earlier rather than later 5

Bottom Line

H2RAs provide a rational, evidence-based alternative to PPIs with lower CDI risk, while TCAs offer a mechanistically different approach for functional dyspepsia that avoids acid suppression entirely. This stepwise algorithm respects patient preferences while maintaining therapeutic efficacy based on current guideline recommendations 4, 5.